Drug intelligence / Profile preview

Therapeutic target tailored chemotherapy-Grupo Hospital de Madrid-rectal cancer

Development stage: Unknown
Lead developer: HM Hospitals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

Therapeutic target tailored chemotherapy-Grupo Hospital de Madrid-rectal cancer is a personalized neoadjuvant treatment protocol designed for patients with localized rectal carcinoma. Developed by Grupo Hospital de Madrid, the regimen utilizes a backbone of capecitabine (an antimetabolite) in combination with intensity-modulated radiotherapy (IMRT). The addition of further cytotoxic or targeted agents is tailored to the individual tumor's molecular profile: irinotecan is included for Topoisomerase-1 positive tumors, oxaliplatin for Topoisomerase-1 negative and ERCC-1 negative tumors, and either bevacizumab or cetuximab is selected based on K-Ras and B-Raf mutation status. This precision medicine approach aims to optimize the pathological complete response rate and improve long-term disease-free survival by matching the chemotherapy components to specific therapeutic targets.

Other names: Therapeutic target tailored chemotherapyTT-tailored chemotherapyTailored Chemotherapy and IMRT in Rectal Carcinoma

Targets

TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)DNATOP1 (DNA Topoisomerase I)EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on Therapeutic target tailored chemotherapy-Grupo Hospital de Madrid-rectal cancer.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Therapeutic target tailored chemotherapy-Grupo Hospital de Madrid-rectal cancer.

Explore the full profile